NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Nutshell Therapeutics

Nutshell Therapeutics

Private
ShanghaiHealthcare & Life Scienceshttp://allonutshell.com/

Last Round

Series A

Extension

Mar 14, 2022

Total Funding Raised

$60M

Company Overview

Nutshell Therapeutics is a biotechnology company that develops small molecule drugs for challenging targets using its proprietary AI-driven allosteric drug discovery platform, AlloStar.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Medical AI

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Infrastructure

Keywords

drug discoveryallosteric drugssmall-molecule drugsai drug discoverybiotechcomputational biologyundruggable targetsin silico drug designoncology therapeuticsprotein modulationclinical-stage biotechdrug development pipelinebiopharmar&d platformpharma licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nutshell Therapeutics Comparables

Compare Nutshell Therapeutics with similar companies based on industry and business-model similarity.

Nutshell Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Atavistik Bio
85%
HotSpot Therapeutics
82%
UCDOM BioTech (Shanghai) Co., Ltd.
79%

Nutshell Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionMar 14, 2022
Series AJan 13, 2022
VC RoundSep 6, 2015

Key People

Founding team and executive leadership

Guoqiang Zhou

Co-Founder & Chief Discovery Officer

Founding Team

qiancheng shen

Chief Executive Officer

Executive Team

Nutshell Therapeutics Investors

Notable investors and investment history

Nutshell Therapeutics investors
InvestorRounds
Baidu VenturesSeries A
Northern Light Venture CapitalSeries A
MPCSeries A
Source Code CapitalSeries A
Genesis CapitalSeries A Extension
Kunlun CapitalSeries A
Straylight CapitalVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 14, 2022

    $40M round led by Genesis Capital.

Nutshell Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Nutshell Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Nutshell Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Employee Range7
Year Founded2013
Last FundingMar 14, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.